Long term efficacy of denosumab for giant cell bone tumours

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=Ki0V-m_PhJ4

Prof Palmerini speaks with ecancer at ESMO 2017 about a phase II trial of denosumab in over 500 patients with giant cell bone cancer, who were treated for up to 8 years. • She describes the significant improvements in patient recovery and quality of life compared to surgical interventions, with even the 34% of patients who relapsed responding to subsequent denosumab, and the suitability of denosumab following surgery. • Prof Palmerini describes the toxicity profile as manageable, noting early intervention with any osteonecrosis of the jaw as the best course of action, and recommends denosumab for most eligible patients. • More from ESMO 2017 : http://ecancer.org/conference/722-esm... • Ecancer website: http://ecancer.org/video/index.php • Twitter: @ecancer • Facebook: / ecancer • ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

#############################

New on site